Stoke Therapeutics reported a net margin of -660.78% for the quarter ended Jun 2026. These financial ratios cover 29 quarters of results from Jun 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||||||||
| EBT Margin | -843.70% | -799.44% | -900.28% | -786.32% | -468.03% | -1,331.84% | -743.14% | -963.56% | -625.57% | -531.88% | -540.05% | -47.24% | 71.99% | -169.96% | -372.70% | -4,124.39% | -802.75% | -660.78% | |||||||||||
| EBIT Margin | -826.50% | -781.12% | -934.53% | -831.58% | -479.23% | -1,340.67% | -823.28% | -1,055.89% | -672.96% | -607.37% | -613.06% | -60.37% | 70.15% | -197.58% | -405.30% | -4,382.24% | -857.57% | -701.65% | |||||||||||
| EBITDA Margin | -826.50% | -781.12% | -934.53% | -831.58% | -479.23% | -1,340.67% | -823.28% | -1,055.89% | -672.96% | -607.37% | -613.06% | -60.37% | 70.15% | -197.58% | -405.30% | -4,382.24% | -857.57% | -701.65% | |||||||||||
| Operating Margin | -826.50% | -781.12% | -934.53% | -831.58% | -479.23% | -1,340.67% | -823.28% | -1,055.89% | -672.96% | -607.37% | -613.06% | -60.37% | 70.15% | -197.58% | -405.30% | -4,382.24% | -857.57% | -701.65% | |||||||||||
| Net Margin | -843.70% | -799.44% | -900.28% | -786.32% | -468.03% | -1,331.84% | -743.14% | -963.56% | -625.57% | -531.88% | -540.05% | -47.24% | 71.19% | -169.96% | -360.68% | -4,124.39% | -802.75% | -660.78% | |||||||||||
| FCF Margin | 1,055.00% | -637.88% | -829.12% | -697.12% | -425.10% | -897.18% | -533.40% | -745.11% | -582.97% | -362.72% | -443.77% | -102.75% | 83.04% | -185.11% | -286.85% | -2,188.73% | -978.25% | -628.00% | |||||||||||
| Efficiency | |||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 259.11M | 246.32M | 277.40M | 308.68M | 289.53M | 266.85M | 268.93M | 269.36M | 248.40M | 234.12M | 216.76M | 256.47M | 300.54M | 282.44M | 339.22M | 395.70M | 372.39M | 389.35M | 430.86M | 418.62M | |||||||||
| Asset Utilization RatioAsset Util. | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.13 | 0.56 | 0.51 | 0.55 | 0.47 | 0.07 | 0.07 | ||||||||||||||
| Leverage & Solvency | |||||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | 0.11M | -0.01M | -0.00M | -0.00M | |||||||||||||||||||||||||
| Times Interest Earned | 0.11M | -0.01M | -0.00M | -0.00M | |||||||||||||||||||||||||
| Valuation | |||||||||||||||||||||||||||||
| Price to EarningsP/E | -41.33 | -35.73 | -32.47 | -20.14 | -19.36 | -14.17 | -15.26 | -14.22 | -7.10 | -8.95 | -23.80 | -27.50 | -24.62 | -55.79 | 3.22 | -26.45 | -33.78 | -32.34 | -40.53 | -33.14 | |||||||||
| Price to SalesP/S | 273.96 | 161.02 | 174.26 | 111.39 | 71.42 | 189.39 | 52.76 | 86.20 | 148.89 | 146.27 | 132.95 | 26.35 | 2.29 | 44.95 | 121.83 | 0.00M | 325.34 | 218.96 | |||||||||||
| Price to BookP/B | 3.94 | 4.07 | 3.42 | 2.32 | 2.48 | 1.97 | 1.72 | 2.47 | 1.01 | 1.51 | 4.47 | 2.91 | 2.80 | 2.60 | 1.04 | 1.85 | 4.20 | 5.31 | 5.13 | 5.91 | |||||||||
| Enterprise Value | 699.54M | 665.48M | 528.67M | 244.61M | 254.58M | 134.43M | 114.31M | 238.43M | -40.20M | 40.14M | 449.14M | 513.10M | 500.56M | 379.08M | 5.74M | 373.40M | 1,047.01M | 1,585.51M | 1,683.00M | 1,748.99M | |||||||||
| EV to EBIT | -30.84 | -27.13 | -21.32 | -9.69 | -9.38 | -4.95 | -4.63 | -7.17 | 1.48 | -1.36 | -15.83 | -17.49 | -16.68 | -27.77 | 0.05 | -13.68 | -24.30 | -25.81 | -31.51 | -26.73 | |||||||||
| EV to EBITDA | -30.84 | -27.13 | -21.32 | -9.69 | -9.38 | -4.95 | -4.63 | -7.17 | 1.48 | -1.36 | -15.83 | -17.49 | -16.68 | -27.77 | 0.05 | -13.68 | -24.30 | -25.81 | -31.51 | -26.73 | |||||||||
| Market Capitalization | 935.69M | 885.29M | 821.89M | 520.24M | 506.24M | 364.03M | 367.98M | 469.88M | 174.51M | 241.53M | 627.72M | 706.65M | 650.65M | 595.98M | 363.06M | 621.11M | 1,295.32M | 1,870.18M | 2,026.55M | 2,041.81M | |||||||||
| Price to FCFP/FCF | -62.57 | -53.56 | 25.97 | -25.24 | -21.02 | -15.98 | -16.80 | -21.11 | -9.89 | -11.57 | -25.54 | -40.33 | -29.96 | -25.65 | 2.76 | -24.28 | -42.47 | -60.95 | -33.26 | -34.87 | |||||||||
| EV to FCF | -46.78 | -40.26 | 16.70 | -11.87 | -10.57 | -5.90 | -5.22 | -10.71 | 2.28 | -1.92 | -18.27 | -29.28 | -23.05 | -16.32 | 0.04 | -14.60 | -34.33 | -51.67 | -27.62 | -29.87 | |||||||||
| EV to CFO | -47.65 | -40.93 | 16.27 | -12.27 | -11.54 | -6.01 | -5.35 | -10.94 | 2.33 | -1.94 | -18.28 | -29.36 | -23.16 | -16.34 | 0.04 | -14.69 | -34.48 | -52.06 | -27.78 | -30.91 | |||||||||
| Return Ratios | |||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -826.50% | -781.12% | -934.53% | -831.58% | -479.23% | -1,340.67% | -823.28% | -1,055.89% | -672.96% | -607.37% | -613.06% | -60.37% | 70.15% | -197.58% | -405.30% | -4,382.24% | -857.57% | -701.65% | |||||||||||
| Return on Capital Employed [ROCE]ROCE | -30.79% | -37.55% | -36.95% | -34.60% | -39.01% | -44.32% | -43.91% | -45.36% | -50.34% | -56.46% | -65.38% | -54.03% | -46.80% | -41.82% | 12.98% | 11.28% | 8.22% | -6.21% | -47.49% | -59.30% | |||||||||
| Return on Assets [ROA]ROA | -29.38% | -35.04% | -34.17% | -31.93% | -35.25% | -38.60% | -37.85% | -40.47% | -43.25% | -46.45% | -51.21% | -40.41% | -35.10% | -31.58% | 14.76% | 13.21% | 10.84% | -1.74% | -39.38% | -49.64% |